



NAVANA PHARMA

NAVANA PHARMACEUTICALS PLC.

Corporate Office : House # 99, Road #04, Block # B,
Banani, Dhaka - 1213

PRICE SENSITIVE INFORMATION

This is for kind information to all valued shareholders of Navana Pharmaceuticals PLC. and stakeholders that the Board of Directors of the company in its 38th meeting held on 28th April, 2024 ended at 4.00 p.m. has considered and approved, among others, the Un-audited Financial Statements for the Third quarter (Q3) period ended on March 31, 2024 and took the following Price Sensitive Decision:-

Comparative Statement on Un-audited Financial Statement for the third quarter (Q3) financial year-2023-2024 period ended on March 31, 2024:

Sl. No	Particulars	01.07.2023-31.03.2024	01.07.2022-31.03.2023	01.01.2024-31.03.2024	01.01.2023-31.03.2023
I	Earnings Per Share (EPS)	3.09	2.57	1.00	1.09
ii	Net Operating Cash Flow Per Share(NOCFPS)	1.59	2.85	N/A	N/A
		As at 31.03.2024	As at 30.06.2023		
iii	Net Asset Value (NAV)	4,523,469,312	4,372,445,072	N/A	N/A
iv	Net Asset Value Per Share	42.11	40.71	N/A	N/A

Notes:

● **Reasons of significant deviation in earning per share (EPS) and Net Operating Cash Flows Per share (NOCFPS) between the periods:**

- ★ EPS: Increment of Earnings per Share up to the reporting period because of growth of Sales Revenue and Gross Profit as well as optimum cost management policy.
- ★ NOCFPS: Due to the quick payment strategy to suppliers & others, Net Cash Flow from Operating Activities has decreased in the reporting period, resulting in decreased NOCFPS.

- In compliance with the Dhaka & Chittagong Stock Exchange (Listing) Regulation, 2015, the company will publish the Un-audited Financial Statement for the third quarter (Q3) period ended on March 31, 2024 in two widely circulated daily newspapers (one in Bengali and otherone in English) and also in an online news portal. The Un-audited Financial Statements for the third quarter (Q3) in details will be available in the website (www.navanapharma.com) of the company.

Dated: April 28, 2024

By order of the Board
Sd/-
Lorens Shamol Mollick FCS
Company Secretary